US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Weight Loss Drugs

1,290.03

+40.333.23%

Number of Gainers:6

Number of Losers:1

Number of Flat:- -

PE:- -

High:1,301.32

Open:1,249.67

Low:1,249.67

Close:1,249.70

Loading ...

Pfizer : Leerink Partners Cuts Target Price to $26 From $28

THOMSON REUTERS

Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?

Is Healthcare Losing the Status of Safe Haven? ETFs in Focus

Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain

Pfizer Reports Strong Q1 2025 Results and Reaffirms Guidance

Late-Trading Activity (4 p.m. - 6 p.m. Eastern Time)

Health Care Climbs Amid Mixed Earnings - Health Care Roundup

Bring on RFK Jr.'s food-dye ban

Pfizer Stock's 7% Yield Makes It Look Like a Junk Bond -- But Better -- Barrons.com

Update: Novo Nordisk Partners With Hims to Sell Wegovy at Reduced Price; Shares Rise

MT Newswires Live

BUZZ-Pfizer beats quarterly profit beat, maintains 2025 forecast; shares rise

Why Viking Therapeutics Stock Popped Again Today

Pfizer Shares Reverse Course, Last up 4.3%

THOMSON REUTERS

Pfizer Shares Rise After Q1 Profit Beats, Reaffirms 2025 Outlook

Hims & Hers Soars 40% as Novo Nordisk Expands Wegovy Access via Telehealth

Pfizer Reports Mixed First Quarter, Affirms Full-Year Outlook

Pfizer CEO Bourla Says Co "Not Going to Be a Strong Top Line Growth Story for Next Three Years, Given Loes, We Expect to Become EPS Growth Story"

THOMSON REUTERS

Pfizer CEO Says Co Has "Ample Room IF There Is a Need to Transfer Production" of Medicines to United States - Conf Call

THOMSON REUTERS

Pfizer Eyes Acquisitions After Obesity Drug Setback

Hims & Hers Skyrockets 33% After Tapping the $499 Weight-Loss Goldmine

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4599/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4599","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","market":"US","secType":"PLATE","nameCN":"Weight Loss Drugs","latestPrice":1290.0328,"timestamp":1746202511445,"preClose":1249.7039,"halted":0,"volume":33060296,"delay":0,"changeRate":0.032271,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":40.328979,"latestTime":"05-02 12:15:11 EDT","open":1249.6709,"high":1301.315,"low":1249.6709,"amount":4368218782.684103,"amplitude":0.041325,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746216000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":10.663316,"peRate":37.494675,"turnoverRate":0.00313,"increases":6,"decrements":1,"flats":0,"marketCap":1381864426368,"floatMarketCap":1292592934688},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","high":1301.315,"amplitude":0.041325,"preClose":1249.7039,"low":1249.6709,"pbRate":"10.663316","latestPrice":1290.0328,"volume":33060163,"delay":0,"open":1249.6709,"prevYearClose":1305.0607,"prevWeekClose":1313.4298,"prevMonthClose":1353.2255,"prevQuarterClose":1314.3724,"fiveDayClose":1313.4298,"twentyDayClose":1265.6132,"sixtyDayClose":1394.0055,"secType":"PLATE","market":"US","turnoverRate":0.00313,"peRate":37.494675,"marketCap":1381864426368,"floatMarketCap":1292592934688,"timestamp":1746202511147,"nameCN":"Weight Loss Drugs"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4599\",,,,undefined,":{"bkCode":"BK4599","up":6,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4599\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531081327","title":"Pfizer : Leerink Partners Cuts Target Price to $26 From $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2531081327","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531081327?lang=en_us&edition=fundamental","pubTime":"2025-04-30 18:04","pubTimestamp":1746007496,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nFWN3R81V2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4588","SG9999013999.USD","SG9999002224.SGD","LU0321505439.SGD","SG9999001176.USD","LU0306806265.USD","IE00BBT3K403.USD","BK4599","LU1066051498.USD","LU1066053197.SGD","PFE","SG9999001176.SGD","IE00BLSP4452.SGD","BK4534","IE00B19Z3581.USD","SG9999002232.USD","BK4007","LU0868494617.USD","LU0170899867.USD","LU0225284248.USD","LU0234572021.USD","IE0002270589.USD","LU0456855351.SGD","LU1883839398.USD","IE00B19Z3B42.SGD","BK4533","SG9999003800.SGD","LU1894683348.USD","LU0122379950.USD","LU0058720904.USD","LU1894683264.USD","SG9999011175.SGD","LU1057294990.SGD","IE000M9KFDE8.USD","IE00BLSP4239.USD","BK4550","LU0306807586.USD","LU0289739699.SGD","LU0985481810.HKD","BK4581","LU0321505868.SGD","BK4592","BK4585","LU1023059063.AUD","SGXZ57979304.SGD","LU0225771236.USD"],"gpt_icon":0},{"id":"2531024397","title":"Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?","url":"https://stock-news.laohu8.com/highlight/detail?id=2531024397","media":"Motley Fool","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531024397?lang=en_us&edition=fundamental","pubTime":"2025-04-30 16:51","pubTimestamp":1746003060,"startTime":"0","endTime":"0","summary":"Altimmune and Viking Therapeutics have promising obesity drugs and could be great acquisition targets for Pfizer.Pfizer should be able to easily fund an acquisition of either small drugmaker.However, Pfizer could hold off on the acquisitions front to see how its obesity drug PF-07976016 fares in clinical testing.The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies. Eli Lilly and Novo Nordisk are already raking in billions of dollars in sales with their weight-loss drugs. Other drugmakers are eyeing the market as well.Pfizer  is certainly in that group. However, the company finds itself at a distinct disadvantage after it recently threw in the towel on experimental obesity pill danuglipron because of safety concerns. Could Pfizer solve the issue by acquiring an up-and-coming biotech with a promising obesity drug in clinical development?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/04/30/will-pfizer-will-acquire-altimmune-or-viking-thera/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["IE00BBT3K403.USD","IE000M9KFDE8.USD","IE00B19Z3B42.SGD","LU0225284248.USD","LU1023059063.AUD","LU1894683348.USD","BK4599","LU0170899867.USD","LU0058720904.USD","SG9999001176.USD","IE00BLSP4239.USD","LU0456855351.SGD","BK4588","BK4007","LU0225771236.USD","IE00BLSP4452.SGD","LU0321505868.SGD","VKTX","SG9999002232.USD","LU1066053197.SGD","LU0985481810.HKD","SG9999001176.SGD","SG9999011175.SGD","LU0306807586.USD","BK4550","BK4534","BK4568","BK4592","LU0868494617.USD","LU1894683264.USD","LU0122379950.USD","BK4139","BK4585","LU0306806265.USD","LU0321505439.SGD","LU1057294990.SGD","PFE","SG9999003800.SGD","LU1883839398.USD","LU0234572021.USD","LU1066051498.USD","LU0289739699.SGD","SGXZ57979304.SGD","IE0002270589.USD","SG9999002224.SGD","SG9999013999.USD","BK4581","BK4533","IE00B19Z3581.USD"],"gpt_icon":1},{"id":"2531085141","title":"Is Healthcare Losing the Status of Safe Haven? ETFs in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2531085141","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531085141?lang=en_us&edition=fundamental","pubTime":"2025-04-30 16:33","pubTimestamp":1746001980,"startTime":"0","endTime":"0","summary":"Healthcare stocks have traditionally been seen as a safe haven during market volatility. However, recent developments — particularly President Trump's tariffs and research spending cuts — are changing that perception.Historically, healthcare has been among the strongest sectors during late-cycle economies and recessionary periods. The sector has always been considered as a safe area for investors seeking shelter amid broader economic uncertainty. However, the sector is facing new challenges in the Trump administration’s first 100 days.Investor interest in healthcare has been waning for some time. President Trump’s policies are introducing fresh uncertainty. This is making both small- and large-cap healthcare stocks less appealing.A recent example is Medpace MEDP, a small clinical research firm specializing in biotech clinical trials. After reporting slower business in its first-quarter earnings. Uncertainty around regulatory changes in Washington continues to weigh heavily on the indus","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/healthcare-losing-status-safe-haven-083300838.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4137","BK4592","IHE","LU0058720904.USD","LU0122379950.USD","FDN","IVV",".SPX","MEDP","XLV","SSO","LU1023059063.AUD","SG9999001176.SGD","LU1066051498.USD","BK4504","XHS","BK4559","IE00BLSP4452.SGD","SG9999013999.USD","OEX","LU0985481810.HKD","ESmain","LU0225771236.USD","IDNA","UPRO","HCSG","PFE","SPY","IE0002270589.USD","LU0170899867.USD","IE00BBT3K403.USD","IE00B19Z3581.USD","LU0225284248.USD","LU2065170008.USD","BK4121","LU0321505868.SGD","OEF","SDS","SH","LU0321505439.SGD","LU0306806265.USD","VOO","LU2065171311.SGD","BK4550","LU2065171402.SGD","LU1894683264.USD","IE000M9KFDE8.USD","SPXU","BK4534","BK4599"],"gpt_icon":1},{"id":"2531708938","title":"Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain","url":"https://stock-news.laohu8.com/highlight/detail?id=2531708938","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531708938?lang=en_us&edition=fundamental","pubTime":"2025-04-30 15:15","pubTimestamp":1745997300,"startTime":"0","endTime":"0","summary":"Both Pfizer and Viking aim to enter the high-growth weight loss drug market.Analysts forecast this market could be worth as much as $130 billion just a few years from now.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/04/30/prediction-pfizers-loss-may-be-viking-therapeutics/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["IE00BLSP4239.USD","IE00B19Z3581.USD","SG9999001176.SGD","LU1066053197.SGD","BK4534","LU1066051498.USD","VKTX","SG9999001176.USD","LU0122379950.USD","BK4581","LU1894683348.USD","BK4139","LU1894683264.USD","LU0321505868.SGD","BK4592","IE00BBT3K403.USD","BK4550","SG9999002224.SGD","IE00B19Z3B42.SGD","BK4599","LU0306806265.USD","SG9999002232.USD","BK4585","SG9999013999.USD","LU0225284248.USD","LU0289739699.SGD","LU1057294990.SGD","SG9999003800.SGD","SG9999011175.SGD","BK4588","LU1023059063.AUD","LU0306807586.USD","LU0456855351.SGD","BK4533","IE00BLSP4452.SGD","LU0170899867.USD","PFE","LU0321505439.SGD","LU0234572021.USD","BK4007","LU0058720904.USD","LU0868494617.USD","LU0985481810.HKD","IE000M9KFDE8.USD","LU1883839398.USD","LU0225771236.USD","IE0002270589.USD","SGXZ57979304.SGD","BK4568"],"gpt_icon":1},{"id":"2531720386","title":"Pfizer Reports Strong Q1 2025 Results and Reaffirms Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2531720386","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531720386?lang=en_us&edition=fundamental","pubTime":"2025-04-30 12:38","pubTimestamp":1745987926,"startTime":"0","endTime":"0","summary":"Pfizer Inc ( ($PFE) ) has released its Q1 earnings. Here is a breakdown of the information Pfizer Inc presented to its investors. Pfizer Inc., a le...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pfizer-reports-strong-q1-2025-results-and-reaffirms-guidance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pfizer-reports-strong-q1-2025-results-and-reaffirms-guidance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0456855351.SGD","BK4599","BK4534","BK4581","BK4592","LU0234572021.USD","LU1057294990.SGD","BK4585","PFE","BK4533","IE00BLSP4239.USD","SG9999002232.USD","LU1883839398.USD","SG9999013999.USD","LU1066051498.USD","IE00B19Z3B42.SGD","IE00BBT3K403.USD","LU0306807586.USD","LU0058720904.USD","LU0225284248.USD","LU0321505868.SGD","SG9999011175.SGD","LU0225771236.USD","IE0002270589.USD","LU1894683264.USD","IE00BLSP4452.SGD","BK4568","BK4007","IE00B19Z3581.USD","LU1023059063.AUD","IE000M9KFDE8.USD","LU0306806265.USD","LU0122379950.USD","LU1066053197.SGD","SG9999003800.SGD","SG9999001176.SGD","LU0289739699.SGD","LU0868494617.USD","LU1894683348.USD","SG9999001176.USD","SGXZ57979304.SGD","LU0321505439.SGD","SG9999002224.SGD","LU0985481810.HKD","BK4588","LU0170899867.USD","BK4550"],"gpt_icon":0},{"id":"2531163716","title":"Late-Trading Activity (4 p.m. - 6 p.m. Eastern Time)","url":"https://stock-news.laohu8.com/highlight/detail?id=2531163716","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531163716?lang=en_us&edition=fundamental","pubTime":"2025-04-30 06:18","pubTimestamp":1745965080,"startTime":"0","endTime":"0","summary":"ISSUE                   EXCH   VOL        LAST     NET CHG       % CHG. SPDR S&P 500                 4,227.0      553.79       —0.53        —0.1. SPDR Blm HY Bd               4,012.1       95.10       —0.17        —0.2","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","IE00B3T34201.USD","LU1894683264.USD","LU0321505868.SGD","BK4209","IE0002270589.USD","BK4579","BK4512","BK4527","BK4592","BK4529","LU0058720904.USD","BK4543","LU1883839398.USD","IE00BLSP4239.USD","BK4568","BK4576","LU0306806265.USD","LU1066051498.USD","SG9999003800.SGD","BK4141","BK4610","LU0122379950.USD","BK4550","NA","LU1057294990.SGD","LU0868494617.USD","BK4534","BK4605","IE00B19Z3581.USD","LU0456855351.SGD","LU0321505439.SGD","BK4585","LU0234572021.USD","SBUX","LU2543165471.USD","BK4508","BK4007","BK4504","BK4599","NC","BK4588","LU0306807586.USD","SG9999001176.USD","EML","LU0170899867.USD","BK4535"],"gpt_icon":1},{"id":"2531900657","title":"Health Care Climbs Amid Mixed Earnings - Health Care Roundup","url":"https://stock-news.laohu8.com/highlight/detail?id=2531900657","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531900657?lang=en_us&edition=fundamental","pubTime":"2025-04-30 05:06","pubTimestamp":1745960760,"startTime":"0","endTime":"0","summary":"Pfizer reaffirmed its outlook for the year, and announced another round of cost cuts as the beleaguered drugmaker looks to turn around its business postpandemic.Hims & Hers shares soared after it struck a deal with Danish obesity-drug maker Novo Nordisk to sell its popular Wegovy drug online. Shares of Novo Nordisk rose, but remain down by about 25% for the year to date.Merck & Co. will grow its U.S. manufacturing footprint with a $1 billion plant in Delaware, becoming the latest drugmaker to invest in the U.S. as tariffs targeting the industry loom.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4592","IE00BLSP4239.USD","SG9999013999.USD","LU0234572021.USD","SG9999011175.SGD","IE00B19Z3581.USD","BK4588","LU0456855351.SGD","LU0306806265.USD","BK4534","LU1894683264.USD","SG9999003800.SGD","SGXZ57979304.SGD","LU0321505439.SGD","BK4581","IE0002270589.USD","LU0225284248.USD","IE00B19Z3B42.SGD","BK4550","LU0985481810.HKD","PFE","SG9999001176.USD","IE00BBT3K403.USD","LU0225771236.USD","IE000M9KFDE8.USD","LU0122379950.USD","LU0170899867.USD","LU1066051498.USD","LU0058720904.USD","BK4599","BK4585","LU1023059063.AUD","SG9999001176.SGD","IE00BLSP4452.SGD","LU0289739699.SGD","SG9999002224.SGD","SG9999002232.USD","LU0306807586.USD","BK4568","LU0868494617.USD","BK4533","LU1894683348.USD","LU0321505868.SGD","LU1883839398.USD","BK4007","LU1057294990.SGD","LU1066053197.SGD"],"gpt_icon":1},{"id":"2531760903","title":"Bring on RFK Jr.'s food-dye ban","url":"https://stock-news.laohu8.com/highlight/detail?id=2531760903","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531760903?lang=en_us&edition=fundamental","pubTime":"2025-04-30 02:39","pubTimestamp":1745951940,"startTime":"0","endTime":"0","summary":"Especially if it will raise the price of junk food. Will RFK Jr.'s food dye ban drive up food prices?I have no idea if artificial food dyes really are bad for you. Or if U.S. health secretary Robert Kennedy's plan to ban some of them, announced in recent days, will survive the inevitable legal counterattacks and propaganda of Big Food.But if they are going to raise the price of junk foods, I say: Bring it on.It is news to no one that food prices have risen a long way. Food inflation was one of the many reasons the Democrats lost last year's election. Many people voted for Donald Trump in the hope he would Make American Groceries Affordable Again.That's the equivalent of three 747 jumbo jets, carrying a total of more than 1,300 people, crashing every single day. It works out at around one per minute. Another one of our fellow citizens died, before his or her time, of obes","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","IE00BKVL7J92.USD","BK4532","BK4585","LU0154236417.USD","LU1093756168.USD","LU1093756325.SGD","BK4007","IE00BZ1G4Q59.USD","BK4588"],"gpt_icon":1},{"id":"2531679957","title":"Pfizer Stock's 7% Yield Makes It Look Like a Junk Bond -- But Better -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2531679957","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531679957?lang=en_us&edition=fundamental","pubTime":"2025-04-30 02:11","pubTimestamp":1745950260,"startTime":"0","endTime":"0","summary":"Stock market investors have been punishing Pfizer's stock. Given the stock's generous 7% yield, maybe junk bond investors should take a look.The venerable drug company, which also developed one of the first Covid-19 vaccines, has seen its share price languish lately. The stock, which peaked at nearly $60 in 2022, has since seen its market value halved -- thanks to coming patent expirations and worries the Trump administration's tariffs could hurt sector profits.On Tuesday, Pfizer reported better-than-expected earnings, but missed Wall Street revenue forecasts. Shares rose about 4% to $24 during the session.The big decline in Pfizer's share price may have a silver lining. The stock now yields 7.4%, according to Morningstar. That's high enough to compete with junk bonds: The iShares iBoxx $ High Yield Corporate Bond ETF, a popular exchange-traded fund, yields 7.5%.And junk bonds could see significant price declines if the economy weakens further and investors begin to seriously worry abo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4592","IE0002270589.USD","LU0868494617.USD","IE00B19Z3B42.SGD","LU1066053197.SGD","LU1894683264.USD","LU0225771236.USD","LU1057294990.SGD","IE00BLSP4239.USD","BK4585","SG9999001176.SGD","BK4550","BK4581","LU0985481810.HKD","SG9999002232.USD","PFE","US6M.BOND","LU0225284248.USD","LU0058720904.USD","BK4588","LU0289739699.SGD","LU0170899867.USD","US5Y.BOND","SG9999001176.USD","LU1023059063.AUD","BK4568","SG9999011175.SGD","BK4533","BK4534","IE00B19Z3581.USD","US30Y.BOND","US12M.BOND","BK4599","BK4007","US10Y.BOND","LU1066051498.USD","SG9999003800.SGD","SG9999002224.SGD","IE00BLSP4452.SGD","HYG","SG9999013999.USD","US3Y.BOND","LU0456855351.SGD","LU1883839398.USD","SGXZ57979304.SGD","US2Y.BOND","US7Y.BOND","LU1894683348.USD","LU0122379950.USD","IE000M9KFDE8.USD"],"gpt_icon":1},{"id":"2531621761","title":"Update: Novo Nordisk Partners With Hims to Sell Wegovy at Reduced Price; Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2531621761","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531621761?lang=en_us&edition=fundamental","pubTime":"2025-04-30 01:09","pubTimestamp":1745946587,"startTime":"0","endTime":"0","summary":"Novo Nordisk A/S  and Hims & Hers Health  partnered to enable US consumers to access NovoCare pharmacy directly through the Hims platform with a bundled offering of all dose strengths of Wegovy and a Hims membership for $599 a month, the companies said Tuesday.Hims shares jumped 26% in recent Tuesday trading, and Novo Nordisk rose 3.6%.Price: 64.89, Change: +2.27, Percent Change: +3.63","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0154236417.USD","BK4585","HIMS","BK4196","BK4007","BK4532","LU1093756168.USD","BK4588","BK7104","LU1093756325.SGD","NVO","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4599","NVO.AU"],"gpt_icon":1},{"id":"2531766423","title":"BUZZ-Pfizer beats quarterly profit beat, maintains 2025 forecast; shares rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2531766423","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531766423?lang=en_us&edition=fundamental","pubTime":"2025-04-30 00:41","pubTimestamp":1745944907,"startTime":"0","endTime":"0","summary":"BUZZ-Pfizer beats quarterly profit beat, maintains 2025 forecast; shares riseUpdates** Pfizer's PFE.N shares rise 4.4% to $24.06. ** Stock set for its biggest single-day pct. jump in nearly 4 months, if gains hold. ** PFE posts Q1 adj. EPS of $0.92, beating analysts' estimates of $0.67, according to data compiled by LSEG** PFE's Q1 revenue misses estimates due to declining sales of its Paxlovid COVID-19 treatment, but co still sticks by FY revenue forecast of $61 billion-$64 billion** Co says it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research operations** Including session's moves, PFE has fallen about 10% YTD ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4N3R721V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE000M9KFDE8.USD","BK4533","SG9999003800.SGD","BK4592","LU0289739699.SGD","BK4581","LU0225771236.USD","BK4599","LU1057294990.SGD","PFE","IE00BLSP4452.SGD","LU1894683348.USD","SG9999002232.USD","LU0234572021.USD","SG9999013999.USD","BK4568","LU1023059063.AUD","IE00BLSP4239.USD","LU1066051498.USD","LU0321505439.SGD","BK4007","SGXZ57979304.SGD","LU0321505868.SGD","LU0058720904.USD","IE0002270589.USD","LU1883839398.USD","LU0868494617.USD","SG9999002224.SGD","LU0306807586.USD","BK4588","LU1894683264.USD","LU1066053197.SGD","LU0170899867.USD","SG9999011175.SGD","LU0225284248.USD","IE00B19Z3581.USD","LU0122379950.USD","BK4534","LU0456855351.SGD","LU0306806265.USD","SG9999001176.SGD","LU0985481810.HKD","BK4585","IE00B19Z3B42.SGD","SG9999001176.USD","IE00BBT3K403.USD","BK4550"],"gpt_icon":1},{"id":"2531765748","title":"Why Viking Therapeutics Stock Popped Again Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2531765748","media":"Motley Fool","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531765748?lang=en_us&edition=fundamental","pubTime":"2025-04-30 00:24","pubTimestamp":1745943840,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald thinks the GLP-1 diet drug VK2735 will be a \"multi-blockbuster\" for Viking stock.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/04/29/why-viking-therapeutics-stock-popped-again-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["VKTX","BK4139","BK4599","BK4585","BK4588"],"gpt_icon":0},{"id":"2531925763","title":"Pfizer Shares Reverse Course, Last up 4.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531925763","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531925763?lang=en_us&edition=fundamental","pubTime":"2025-04-30 00:13","pubTimestamp":1745943200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4N3R721T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4534","BK4588","LU0122379950.USD","LU1066053197.SGD","LU1066051498.USD","IE00BLSP4452.SGD","BK4568","LU1894683264.USD","LU0985481810.HKD","SGXZ57979304.SGD","BK4581","IE00BBT3K403.USD","LU1057294990.SGD","LU0225284248.USD","SG9999001176.USD","IE0002270589.USD","LU1883839398.USD","LU0225771236.USD","LU0868494617.USD","SG9999013999.USD","SG9999002224.SGD","LU0170899867.USD","BK4585","LU0234572021.USD","BK4533","LU0321505868.SGD","BK4550","SG9999011175.SGD","LU0306807586.USD","IE00B19Z3B42.SGD","IE00BLSP4239.USD","PFE","LU1023059063.AUD","LU0058720904.USD","BK4592","LU0321505439.SGD","SG9999001176.SGD","IE000M9KFDE8.USD","LU0306806265.USD","LU0289739699.SGD","BK4007","BK4599","LU1894683348.USD","SG9999003800.SGD","SG9999002232.USD","LU0456855351.SGD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2531762025","title":"Pfizer Shares Rise After Q1 Profit Beats, Reaffirms 2025 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2531762025","media":"GuruFocus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531762025?lang=en_us&edition=fundamental","pubTime":"2025-04-30 00:01","pubTimestamp":1745942472,"startTime":"0","endTime":"0","summary":"Based on the one year price targets offered by 19 analysts, the average target price for Pfizer is $28.71 with a high estimate of $41.43 and a low estimate of $22.00. The average target implies an upside of 21.18% from the current price of $23.69.Based on GuruFocus estimates, the estimated GF Value for Pfizer Inc in one year is $28.58, suggesting an upside of 20.64% from the current price of $23.69.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gurufocus.com/news/2812354/pfizer-shares-rise-after-q1-profit-beats-reaffirms-2025-outlook","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gurufocus_highlight","symbols":["IE000M9KFDE8.USD","BK4533","SG9999003800.SGD","BK4592","LU0289739699.SGD","BK4581","LU0225771236.USD","BK4599","LU1057294990.SGD","PFE","IE00BLSP4452.SGD","LU1894683348.USD","SG9999002232.USD","LU0234572021.USD","SG9999013999.USD","BK4568","LU1023059063.AUD","IE00BLSP4239.USD","LU1066051498.USD","LU0321505439.SGD","BK4007","SGXZ57979304.SGD","LU0321505868.SGD","LU0058720904.USD","IE0002270589.USD","LU1883839398.USD","LU0868494617.USD","SG9999002224.SGD","LU0306807586.USD","BK4588","LU1894683264.USD","LU1066053197.SGD","LU0170899867.USD","SG9999011175.SGD","LU0225284248.USD","IE00B19Z3581.USD","LU0122379950.USD","BK4534","LU0456855351.SGD","LU0306806265.USD","SG9999001176.SGD","LU0985481810.HKD","BK4585","IE00B19Z3B42.SGD","SG9999001176.USD","IE00BBT3K403.USD","BK4550"],"gpt_icon":1},{"id":"2531761220","title":"Hims & Hers Soars 40% as Novo Nordisk Expands Wegovy Access via Telehealth","url":"https://stock-news.laohu8.com/highlight/detail?id=2531761220","media":"GuruFocus.com","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531761220?lang=en_us&edition=fundamental","pubTime":"2025-04-29 23:54","pubTimestamp":1745942055,"startTime":"0","endTime":"0","summary":"Hims & Hers Health  shares soared 40% in premarket trading Tuesday after Novo Nordisk  said it would begin offering its blockbuster weight-loss drug Wegovy through telehealth providers, including HIMS, Ro, and LifeMD.Novo Nordisk stock  climbed 3% following the announcement, which comes as the Danish drugmaker moves to solidify access to Wegovy amid rising demand and tighter restrictions on compounded alternatives.GuruFocus has detected 3 Warning Sign with HIMS.The new collaboration allows patients to receive Wegovy via direct-to-consumer channels like NovoCare, Novo Nordisk's online pharmacy, which integrates with the telehealth platforms. The drug will be offered at a discounted rate of $499 per month through NovoCare for patients without insurance.Hims & Hers will begin providing all Wegovy dose sizes this week, with added services such as 24/7 clinical care and nutritional support. The total monthly cost will start at $599.The shift comes as compounded semaglutide, cheaper, unappro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hims-hers-soars-40-novo-155415633.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0154236417.USD","BK4599","BK4585","BK4532","LU1093756168.USD","BK4007","BK4196","NVO","HIMS","LU1093756325.SGD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4588"],"gpt_icon":1},{"id":"2531752767","title":"Pfizer Reports Mixed First Quarter, Affirms Full-Year Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2531752767","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531752767?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:47","pubTimestamp":1745938030,"startTime":"0","endTime":"0","summary":"Pfizer's  first-quarter earnings unexpectedly increased year on year even as sales fell below Wall Street's estimates, while the pharmaceutical giant reiterated its full-year outlook.Adjusted per-share earnings rose to $0.92 from $0.82 a year earlier and surpassed the consensus on FactSet of $0.67. Revenue fell 8% to $13.72 billion, below analysts' $13.92 billion estimate.For 2025, the company continues to expect adjusted EPS guidance of $2.80 to $3 and revenue of $61 billion to $64 billion. Analysts are looking for non-GAAP EPS of $2.94 on revenue of $62.75 billion. In the previous year, adjusted EPS surged 69% to $3.11, while sales rose 7% to $63.63 billion.\"In addition, we have identified additional opportunities to drive improvements in productivity and operational efficiency in our  organization through enhanced digital enablement and automation,\" according to the CFO. \"We expect approximately $500 million in savings associated with these efforts to be realized by the end of 2026 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-reports-mixed-first-quarter-144710844.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4550","LU0225284248.USD","LU0456855351.SGD","LU0306806265.USD","SG9999011175.SGD","IE00BBT3K403.USD","SG9999013999.USD","SGXZ57979304.SGD","SG9999003800.SGD","LU1883839398.USD","LU1894683264.USD","LU0289739699.SGD","LU0234572021.USD","BK4568","SG9999002232.USD","LU0306807586.USD","IE00BLSP4239.USD","BK4588","LU1023059063.AUD","PFE","BK4592","SG9999001176.SGD","LU0321505439.SGD","BK4585","LU1894683348.USD","LU0170899867.USD","BK4599","IE0002270589.USD","BK4533","LU0122379950.USD","IE00B19Z3B42.SGD","SG9999001176.USD","SG9999002224.SGD","LU1057294990.SGD","LU0058720904.USD","BK4534","LU0225771236.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","LU1066053197.SGD","BK4007","IE00BLSP4452.SGD","LU0868494617.USD","LU1066051498.USD","LU0985481810.HKD","LU0321505868.SGD","BK4581"],"gpt_icon":1},{"id":"2531751132","title":"Pfizer CEO Bourla Says Co \"Not Going to Be a Strong Top Line Growth Story for Next Three Years, Given Loes, We Expect to Become EPS Growth Story\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2531751132","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531751132?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:42","pubTimestamp":1745937769,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R726B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999013999.USD","LU1894683264.USD","LU0225771236.USD","LU0321505868.SGD","IE0002270589.USD","BK4581","PFE","LU0058720904.USD","IE000M9KFDE8.USD","IE00BLSP4452.SGD","BK4592","SG9999002224.SGD","SG9999002232.USD","LU0289739699.SGD","LU1023059063.AUD","LU1883839398.USD","IE00BLSP4239.USD","BK4568","LU0306806265.USD","LU1066051498.USD","SG9999003800.SGD","SG9999001176.SGD","LU0225284248.USD","LU0122379950.USD","BK4550","LU1057294990.SGD","LU0868494617.USD","BK4534","IE00B19Z3581.USD","LU1894683348.USD","LU0456855351.SGD","IE00B19Z3B42.SGD","BK4585","LU0321505439.SGD","LU0234572021.USD","SG9999011175.SGD","BK4533","BK4007","BK4599","BK4588","LU0306807586.USD","IE00BBT3K403.USD","SG9999001176.USD","LU1066053197.SGD","LU0985481810.HKD","LU0170899867.USD","SGXZ57979304.SGD"],"gpt_icon":0},{"id":"2531594047","title":"Pfizer CEO Says Co Has \"Ample Room IF There Is a Need to Transfer Production\" of Medicines to United States - Conf Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2531594047","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531594047?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:42","pubTimestamp":1745937769,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R726B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0321505868.SGD","IE00B19Z3B42.SGD","BK4550","BK4581","LU0225771236.USD","LU0225284248.USD","BK4568","LU0058720904.USD","LU0170899867.USD","SGXZ57979304.SGD","BK4599","LU1057294990.SGD","IE00B19Z3581.USD","LU0321505439.SGD","LU1066053197.SGD","LU0306807586.USD","IE000M9KFDE8.USD","LU1883839398.USD","LU1894683264.USD","LU0456855351.SGD","SG9999002232.USD","BK4585","LU1894683348.USD","SG9999003800.SGD","SG9999001176.SGD","LU0985481810.HKD","LU0289739699.SGD","BK4534","BK4592","PFE","SG9999002224.SGD","LU0868494617.USD","BK4533","SG9999001176.USD","LU0306806265.USD","IE0002270589.USD","IE00BLSP4452.SGD","BK4007","BK4588","SG9999011175.SGD","LU0234572021.USD","IE00BBT3K403.USD","LU0122379950.USD","LU1023059063.AUD","IE00BLSP4239.USD","LU1066051498.USD","SG9999013999.USD"],"gpt_icon":0},{"id":"2531751895","title":"Pfizer Eyes Acquisitions After Obesity Drug Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2531751895","media":"GuruFocus.com","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531751895?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:32","pubTimestamp":1745937141,"startTime":"0","endTime":"0","summary":"Pfizer  is overhauling its cardiometabolic pipeline and weighing acquisitions after an oral weight-loss candidate stumbled, even as its Q1 results delivered a mixed bag of beats and misses.GuruFocus has detected 6 Warning Signs with PFE.The New Yorkbased drugmaker reported $13.7 billion in first-quarter revenue, roughly $400 million shy of analysts' $14.09 billion consensus, but topped bottom-line forecasts and confirmed its 2025 earnings outlook.Revenue slid about 8% year-over-year, driven largely by a steep drop in Paxlovid sales to $491 million versus a $902 million forecast. That decline was only partly offset by Comirnaty, Pfizer's COVID vaccine co-developed with BioNTech, which generated $565 million and outpaced the $325.5 million estimate.He added that Pfizer would build our cardiometabolic pipeline, including in obesity, by advancing internal programs such as our GIPR antagonist and pursuing external opportunities that could include partnerships or acquisitions. That strategic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-eyes-acquisitions-obesity-drug-143221205.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","LU0321505439.SGD","SG9999001176.USD","IE00BBT3K403.USD","LU0289739699.SGD","IE00B19Z3581.USD","LU0122379950.USD","BK4592","LU1894683264.USD","LU0321505868.SGD","BK4533","BK4588","LU0225771236.USD","SG9999013999.USD","PFE","SG9999002224.SGD","LU0456855351.SGD","LU1066053197.SGD","LU0306806265.USD","SG9999003800.SGD","LU0170899867.USD","BK4581","LU1894683348.USD","LU1883839398.USD","IE00B19Z3B42.SGD","IE00BLSP4452.SGD","SG9999011175.SGD","BK4585","SGXZ57979304.SGD","LU1066051498.USD","BK4007","LU0225284248.USD","IE00BLSP4239.USD","LU0058720904.USD","IE0002270589.USD","BK4599","LU0868494617.USD","LU1057294990.SGD","LU0306807586.USD","LU1023059063.AUD","SG9999001176.SGD","LU0234572021.USD","SG9999002232.USD","BK4534","LU0985481810.HKD","IE000M9KFDE8.USD","BK4550"],"gpt_icon":1},{"id":"2531752750","title":"Hims & Hers Skyrockets 33% After Tapping the $499 Weight-Loss Goldmine","url":"https://stock-news.laohu8.com/highlight/detail?id=2531752750","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531752750?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:27","pubTimestamp":1745936829,"startTime":"0","endTime":"0","summary":"Hims & Hers Health  shares exploded 33% at 8:10 am in the premarket trading today after announcing a major expansion of its telehealth weight-loss offerings through a new direct partnership with Novo Nordisk's  NovoCare Pharmacy. Patients can now access authentic, FDA-approved Wegovy through Hims & Hers, LifeMD, and Ro, using a streamlined self-pay model priced at $499 per month. With supply fully restored, the move positions Hims & Hers to capitalize on soaring demand as weight-loss treatments reshape the healthcare landscape.Wegovy, first approved in 2021, has rapidly become a game-changer for chronic weight management, offering the first weekly GLP-1 therapy for obesity. Its value grew even stronger in 2024 when the FDA expanded its label to cover cardiovascular risk reduction, helping it reach nearly 1.5 million patients across the U.S. By tapping into Novo Nordisk's direct distribution model, Hims & Hers is not only expanding its footprint in one of the fastest-growing markets but","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hims-hers-skyrockets-33-tapping-142709459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVO","IE00BKVL7J92.USD","BK4599","IE00BZ1G4Q59.USD","LU1093756325.SGD","HIMS","LU0154236417.USD","BK4585","BK4588","BK4532","LU1093756168.USD","BK4007","BK4196"],"gpt_icon":1}],"pageSize":20,"totalPage":11,"pageCount":4,"totalSize":211,"code":"91000000","status":"200"}]}}